Drug Prices and Generic Competition
You would be surprised to find out just how many questions are answered by the analysis of the relationship that […]
You would be surprised to find out just how many questions are answered by the analysis of the relationship that […]
Introduction Valuing pharmaceutical companies is a complex yet crucial task for investors, analysts, and stakeholders. The unique nature of the
Valuation of Pharma Companies: 5 Key Considerations Read Post »
Amid public outcry over rising costs of brand-name drugs, the prices of generic medicines have been falling, raising fears about
This paper was originally published by Melek Simsek, Berrie Meijer, Adriaan A.van Bodegraven, Nanne K.H. de Boer, and Chris J.J.
When referring to “big data” in the context of the drug industry, one should essentially think of a collection of
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
6 Ways to Maximize Product Value as Loss of Exclusivity Approaches Read Post »
Considering switching to DrugPatentWatch? See why others have come to us. DrugPatentWatch Alternatives
This paper was originally published by Ingrid Freije, Stéphane Lamouche, and Mario Tanguay in Therapeutic Innovation & Regulatory Science under
Subscribe to our weekly newsletter below and never miss the latest product or an exclusive offer.